PD L1 News and Research

RSS

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

City of Hope launches trial to map how tumors change during immunotherapy resistance

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system's ability to fight disease.

21 Jul 2026

Thymus hormone identified as key player in reversing age-related inflammation

Chronic, low-grade inflammation in the body-a phenomenon known as "inflammaging" because it increases with age-has been linked to many of today's leading causes of illness and death, including cancer, heart disease, metabolic conditions and neurodegenerative diseases.

21 Jul 2026

Six-gene signature predicts colorectal cancer recurrence after liver metastases

Researchers at The University of Texas MD Anderson Cancer Center identified a six-gene signature in microscopic colorectal cancer (CRC) liver metastases that may help predict recurrence after treatment.

9 Jul 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

New breast cancer classification system predicts immunotherapy response success

The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.

3 Jul 2026

New AI model improves prediction of cancer immunotherapy success

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others.

3 Jul 2026

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Copper-induced cell death stimulates antitumor immune cell responses

A preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Cell, details a connection between the immune system and cuproptosis, a type of copper-induced cell death.

22 Jun 2026

New study frames altered protein modifications as cancer drivers

Cancer has often been explained through mutations in deoxyribonucleic acid (DNA) or changes in ribonucleic acid (RNA), but these layers do not fully explain why tumors with similar genetic profiles can behave differently.

9 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Researchers uncover immune mechanisms behind polycystic kidney disease progression

A new review has illuminated a critical but often overlooked dimension of autosomal dominant polycystic kidney disease (ADPKD)—its immune microenvironment.

24 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Tumor microenvironment markers forecast immunotherapy response in rare cancers

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Turning the flu virus into a powerful tool to fight cancer

A recent Views & Comments article published in Engineering highlights advances in repurposing influenza viruses as flexible therapeutic platforms for infectious diseases and cancer, driven by progress in reverse genetics and viral vector engineering.

14 May 2026

Researchers uncover new mechanism linking metabolism, immunity, and skeletal health

Obesity alters bone health not only through increased body weight but also by reshaping the bone marrow environment.

25 Apr 2026

Path-IO model predicts immunotherapy response in lung cancer patients

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC).

21 Apr 2026

AI model predicts immunotherapy response in lung cancer patients

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026